Companies/EU/ORY

ORYZON GENOMICS S.A.

Last · MCE€2.538-0.14 (-5.23%)stale · yahoo · 41h ago
Vol 619.6K ≈ 1.57M
Market cap€208.0M82.0M sh
P/E · TTM-89.0fwd 282 · eps -0.03 · loss
Beta0.40vs S&P 500
Div yield0.00%annual · TTM
52w range
€2.48€3.81
Volume373.1Ksession

Issuer

Legal nameORYZON GENOMICS S.A.
HQEurope (EU)
ListingEU ORY
ISINES0167733015
LEI95980063R15RDF29DK13
SectorHealthcare
IndustryBiotechnology & Medical Research
CurrencyEUR
Entity registryisin:ES0167733015
Websitewww.oryzon.com
Employees46
AddressOryzon Genomics SA Calle Sant Ferran 74 08940, Barcelona +34 93 515 13 13
Loading chart…

Upcoming earnings

1 event
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.06
Est. revenue
0
View upcoming earnings →

Press & signals

2 recent
  • GlobeNewswire

    ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

  • GlobeNewswire

    ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Documents

FormReporting forFiledFlags
slidesCorporate Presentation. 4Q 2026IR
—2026-10-070
otherORYZON_EESS (06.07.2026) ENG.pdfIR
—2026-07-060
proxyVotaciones_20260626_141222.pdfIR
—2026-06-260
proxyORYZON_JGO 2026_21_Reglamento Interno de Conducta en los Mercados de Valores.pdfIR
—2026-06-010
otherDC-025 rev5 - Reglamento interno de conducta en los mercados de valores de Oryzon Genomics, S.A.pdfIR
—2026-06-010
Showing 5 of 371 filings